



Dkt. No. 62815-A-PCT-US/JPW/GJG/ALW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Douglas J.M. Allen, et al.

Serial No.: 10/716,098 Examiner: T. N. Truong

Filed : November 17, 2003 Group Art Unit: 1624

Title : N-(3-ETHYNYLPHENYL)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATED ANHYDRATE AND MONOHYDRATE

1185 Avenue of the Americas
New York, New York 10036

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Petitioner OSI Pharmaceuticals, Inc., having a place of business at 41 Pinelawn Road, previously 58 South Service Road, Suite 110, Melville, NY 11747, the sole assignee of record of the entire right, title, and interest in and to the above-identified application by virtue of an Assignment, 1) from Timothy Norris, Dinos Santafianos, Douglas J.M. Allen, Ravi M. Shanker and Jeffrey W. Raggon to Pfizer Inc., recorded with the United States Patent and Trademark Office on May 29, 2001 at Reel 011875, Frames 0740-0745 in the parent of the subject application, copy of which is attached hereto as **Exhibit A**; and 2) from Pfizer Inc. to OSI Pharmaceuticals, Inc. recorded on May 29, 2001 at Reel 011849, Frames 0256-0259 in the parent of the subject application, copy of which is attached hereto as **Exhibit B** including a change of address for OSI Pharmaceuticals, Inc., recorded on April 6, 2004 at Reel 015147, Frames 0743-0746 in the subject application, copy of which is attached hereto as **Exhibit C**) hereby disclaims, except as provided below, the terminal portion of the statutory term of any patent granted on the subject application which would extend beyond the expiration date

Applicants: Douglas John Medldrum Allen et al.

Serial No.: 10/716,098

Filed : November 17, 2003

Page 2

of the full statutory term defined in 35 U.S.C. §154 to §156 and §173 of commonly assigned U.S. Patent Nos. 6,706,721.

Petitioner hereby agrees that any patent granted on the subject application shall be enforceable only for and during such period that U.S. Patent No. 6,706,721 and any patent issued from the subject application are commonly owned and that this agreement will run with any patent granted on the subject application and be binding upon the grantee, its successors and assigns.

In making the above disclaimer, Petitioner does not disclaim the terminal portion of any patent granted on the subject application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of U.S. Patent No. 6,706,721 in the event that such patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term.

I certify that I have reviewed the attached Assignment, and that, to the best of my knowledge and belief, OSI Pharmaceuticals, Inc. has the entire right, title and interest in and to the subject application. I further certify that I am authorized to sign this Terminal Disclaimer on behalf of OSI Pharmaceuticals, Inc. as indicated.

Applicants: Douglas John Medldrum Allen et al.

Serial No.: 10/716,098

Filed : November 17, 2003

Page 3

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that any such willful false statement may jeopardize the validity of the application or any patent issued thereon.

OSI PHARMACEUTICALS, INC.

Date: 4/2/2007

By: Barbara A. Wood

Barbara A. Wood, Esq.
Vice President and General Counsel

EXHIBIT 1

Applicants: Douglas J.M. Allen et al.

Application No.: 10/716,098

Filed: November 17, 2003

EXHIBIT A

Applicants: Douglas J.M. Allen et al.

Application No.: 10/716,098

Filed: November 17, 2003



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231**

AUGUST 20, 2001

COOPER & DUNHAM LLP
JOHN P. WHITE
1185 AVENUE OF THE AMERICAS
NEW YORK, NY 10036

PTAS

S.M.B



101739442A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 05/29/2001

REEL/FRAME: 011875/0740
NUMBER OF PAGES: 5

BRIEF: ASSIGNMENT OF ASSIGNEE'S INTEREST (SEE DOCUMENT FOR DETAILS)

ASSIGNOR: ALLEN, DOUGLAS J. M. REC'D. DATE: 10/02/1986

ASSIGNOR: SHANKER, RAVI M. REC'D. DATE: 10/09/2001

ASSIGNOR: FRANCIS J. BAGGON

ASSIGNEE:
Pfizer Inc.
235 East 42nd Street
New York, New York 10017

011875/0740 PAGE 2

SERIAL NUMBER: 09355534
PATENT NUMBER:

FILING DATE: 07/29/1999
ISSUE DATE:

SAUNDRA BALLENGER, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, we, Timothy Norris of 27 Friar Tuck Drive, Gales Ferry, Connecticut, United States Of America; Dinos Santafianos of 93 Gerald Drive, Manchester, Connecticut, United States Of America; Douglas J.M. Allen of 549 Ocean Avenue, New London, Connecticut, United States Of America; Ravi M. Shanker of 600 Meridian Extension, Groton, Connecticut, United States Of America; Jeffrey W. Raggon of 48 Teeocomwas Drive, Uncasville, Connecticut, United States Of America; hereby sell, assign and transfer unto PFIZER INC., a corporation organized and existing under the laws of the State of Delaware, United States of America, and having its principal place of business at 235 East 42nd Street, New York, New York 10017, United States of America, our entire right, title and interest, except as limited hereinbelow, in and to provisional patent application of the United States of America, provisional application number 60/083,441, filed April 29, 1998, and entitled **N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE ANHYDRATE AND MONOHYDRATE**; and our entire right, title and interest, in the United States of America, in and to all our inventions, whether joint or sole, disclosed in said provisional patent application; and our entire right, title and interest in and to all applications filed in the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted in the United States of America on the foregoing applications;

and we hereby sell, assign and transfer unto PFIZER PRODUCTS INC., a corporation organized and existing under the laws of the State of Connecticut, United States of America, and having its place of business at Eastern Point Road, Groton, Connecticut 06340, United States of America,

our entire right, title and interest, in all countries of the world except the United States of America, in and to all our inventions, whether joint or sole, disclosed in said provisional patent application; and our entire right, title and interest in and to all patent applications filed outside the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted outside the United States of America on said patent applications filed outside the United States of America; and the right to claim priority from said provisional patent application under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America is a party and which afford similar priority-claiming privileges, in all countries of the world except the United States of America;

and we hereby agree, whenever requested, to communicate to said PFIZER INC. and said PFIZER PRODUCTS INC., and their successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world.

Signed and witnessed this Oct 1st day of Oct, 1997, at
Groton Connecticut.

Timothy Norris
TIMOTHY NORRIS

In the presence of:

Kristine Birkbeck
Kristine Birkbeck
(Typed or Printed Name of Witness)

Signed and witnessed this 1st day of Oct, 1998, at
Groton Connecticut.

D. S.
DINOS SANTAFIANOS

In the presence of:

Kristine Birkbeck
Kristine Birkbeck
(Typed or Printed Name of Witness)

Signed and witnessed this 2nd day of October, 1998, at
Groton Connecticut.

Douglas J.M. Allen
DOUGLAS J.M. ALLEN

In the presence of:

Kristine Birkbeck
Kristine Birkbeck
(Typed or Printed Name of Witness)

Signed and witnessed this 23 day of October, 1998, at
Groton, Connecticut.

Ravi Shanker
RAVI M. SHANKER

In the presence of:

Brenda Ramos
Brenda Ramos
(Typed or Printed Name of Witness)

Signed and witnessed this 7th day of Oct, 1998, at
Groton Connecticut.



JEFFREY W. RAGGAN

In the presence of:

Kristine Birkbeck

Kristine Birkbeck

(Typed or Printed Name of Witness)

ASSIGNMENT
BY

TIMOTHY NORRIS
DINOS SANTAFIANOS
DOUGLAS J.M. ALLEN
RAVI M. SHANKER
JEFFREY W. RAGGON

TO

PFIZER INC.

Application for Letters Patent
of the United States for:

N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS
(2-METHOXYETHOXY)-4-QUINAZOLINAMINE
MESYLATE ANHYDRATE AND MONOHYDRATE

Attorney ~~for~~ John P. White

Cooper & Dunham LLP
1185 Avenue of the Americas
New York, N.Y. 10036

212-273-4400

EXHIBIT B

Applicants: Douglas J.M. Allen et al.

Application No.: 10/716,098

Filed: November 17, 2003



62814-A
JMW
UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
COPY

AUGUST 14, 2001

COOPER & DUNHAM LLP
JOHN P. WHITE
1185 AVENUE OF THE AMERICAS
NEW YORK, NY 10036

PTAS

SEARCHED
INDEXED
FILED



101738834A

AUG 21 2001

Received
U.S. Patent and Trademark Office
Assignment Division

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 05/29/2001

REEL/FRAME: 011849/0256
NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
PFIZER, INC.

DOC DATE: 04/09/2001

ASSIGNEE:
OSI PHARMACEUTICALS, INC.
106 CHARLES LINDBERGH BLVD.
UNIONDALE, NEW YORK 11553-3649

SERIAL NUMBER: 09711272
PATENT NUMBER:

FILING DATE: 11/09/2000
ISSUE DATE:

SERIAL NUMBER: 09355534
PATENT NUMBER:

FILING DATE: 07/29/1999
ISSUE DATE:

LAZENA MARTIN, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

FORM PTO-1595 (Substitute)

(Rev. 6-96)

To the Honorable Commissioner of Patents and Trademarks

1. Name of conveying party(ies):

Pfizer Inc.

06-05-2001



101738834

5. 29.01

Additional name(s) of conveying party(ies) attached?

 Yes No

3. Nature of Conveyance:

 Assignment
 Security Agreement
 Other _____

 Merger
 Change of Name

Execution Date(s): April 9, 2001

Name: OSI Pharmaceuticals, Inc.

Internal Address: _____

Street Address: 106 Charles Lindbergh Blvd.

City/State/Zip: Uniondale, New York 11553-3649

4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date(s) of the application is(are): _____

A. Patent Application No.(s) U.S. Serial Nos.:

09/355,534, filed July 29, 1999 and

09/711,272, filed November 9, 2000

B. Patent No.(s) _____

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: John P. White

Internal Address: Cooper & Dunham LLP

Street Address: 1185 Avenue of the Americas

City/State/Zip: New York, New York 10036

6. Total number of applications and patents involved: 2

7. Total fee (37 CFR §3.41): \$ 80.00

 Enclosed

 Authorized to be charged to deposit account

8. Deposit account number:

03-3125

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

John P. White
Name of Person Signing

Signature

May 24, 2001

Date

Reg. No. 28,678

Total Number of pages including cover sheet, attachments and document: 4

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

S/John P. White

Date

John P. White
Reg. No. 28,678

OMB No. 0651-0011 (exp. 4/94)

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks

Box Assignments

Washington, D.C. 20231

PATENT ASSIGNMENT

WHEREAS, Pfizer Inc., a corporation duly organized and existing under and by virtue of the laws of the State of Delaware and having a principal place of business at 235 East 42nd Street, New York, New York 10017-5755 (the "Assignor"), is the owner of the entire and exclusive right, title and interest in, to and under the Letters Patent of the United States and applications for Letters Patent in the United States, as identified on Schedule A hereto, and the respective inventions described and claimed therein, along with all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of intellectual property (collectively, the "Patent Rights"); and

WHEREAS, OSI Pharmaceuticals, Inc., a corporation duly organized and existing under and by virtue of the laws of Delaware and having a principal place of business at 106 Charles Lindbergh Boulevard, Uniondale, New York 11553-3649 (the "Assignee"), desires to acquire the entire and exclusive right, title and interest in, to and under the Patent Rights.

NOW, THEREFORE, in consideration of TEN DOLLARS (\$10.00) and other good and valuable consideration paid by the Assignee, the receipt and sufficiency of which is hereby acknowledged, the Assignor hereby sells, assigns, and transfers to the Assignee, its successors and assigns, the entire and exclusive right, title and interest in, to and under the Patent Rights, and all other patent rights that may be based thereon, including all renewals, divisions, substitutes, reissues, continuations, and all reissues or extensions thereof, and every priority right that is or may be predicated upon or arise from said Patent Rights, to the full end of the term and any extensions thereof for which said Patent Rights may be granted as fully and entirely as the same would have been held by the Assignor had this Assignment not been made.

The Assignor hereby acknowledges that this Assignment, being of the entire right, title and interest in and to the Patent Rights, carries with it the right in the Assignee to apply for and obtain from competent authorities, in all countries of the world, any and all Letters Patent by attorneys and agents of the Assignee's selection and the right to procure the grant of all Letters Patent to the Assignee, for its own name as assignee of the entire right, title and interest in and to the Patent Rights.

The Assignor hereby further agrees to execute upon reasonable request any other lawful documents and likewise to perform any other lawful acts which may be reasonable necessary to aid the Assignee, its successors, assigns, and legal representatives, but at its or their expense and charges, to obtain and enforce the Patent Rights.

The Assignor hereby covenants that it has full right to, and hereby does, authorize and request the United States Commissioner of Patents and Trademarks, or other proper governmental authority to issue all Letters Patent or other documents evidencing the Patent Rights to the Assignee, its successors and assigns, in accordance with this Assignment.

SIGNATURE PAGE TO PATENT ASSIGNMENT

PFIZER INC.

Signature: Peter C. Richardson

Name: Peter C. Richardson

Title: Senior Assistant General Counsel
& Assistant Secretary

STATE OF NEW YORK

COUNTY OF NEW YORK

On this 24 day of April, 2001, before me personally appeared Peter C. Richardson of Pfizer Inc. to me known to be the person described in and who executed the foregoing instrument, and acknowledged that he executed the same under the authority of Pfizer Inc. as its free act and deed.

Mary Byrnes
Notary Public

(Notary Seal)

My Commission expires: _____

Mary Byrnes
Notary Public
State of New York
No. 01BY493037
Qualified In New York County
Certificate Filed In
New York County
Commission Expires May 9, 2002

SCHEDULE A

Cooper & Dunham Docket

DESCRIPTION

62815-PCT-US

Douglas J. M. Allen, et al., N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE MESYLATE ANHYDRATE AND MONOHYDRATE, U.S. Serial No. 09/355,534, filed July 29, 1999, which is a §371 national stage of PCT International Application No. PCT/IB99/00612, filed April 8, 1999, which claims the benefit of U.S. Provisional Application No. 60/083,441, filed April 29, 1998

62814-A

Timothy Norris, Jeffrey W. Raggon, Richard D. Connell, James D. Moyer, Michael J. Morin, Shana M. Kajiji, Barbara A. Foster, Karen J. Ferrante and Sandra L. Silberman, Stable Polymorph of N-(3-Ethynylphenylamino)-6,7-Bis(2-Methoxyethoxy)-4-Quinazolinamine Hydrochloride, Methods of Production And Uses Thereof, U.S. Serial No. 09/711,272, filed November 9, 2000, claiming priority of U.S. Provisional Application No. 60/206,420, filed May 23, 2000, U.S. Provisional Application No. 60/193,191, filed March 30, 2000, and U.S. Provisional Application No. 60/164,907, filed November 11, 1999

EXHIBIT C

Applicants: Douglas J.M. Allen et al.

Application No.: 10/716,098

Filed: November 17, 2003



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEPTEMBER 29, 2004

PTAS



102715280A

COOPER & DUNHAM LLP
JOHN P. WHITE
1185 AVENUE OF THE AMERICAS
NEW YORK, NY 10036

OCT - 3 2004

MP2

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 04/06/2004

REEL/FRAME: 015147/0743
NUMBER OF PAGES: 4

BRIEF: CHANGE OF ADDRESS

ASSIGNOR:
OSI PHARMACEUTICALS, INC.

DOC DATE: 04/10/2002

ASSIGNEE:
OSI PHARMACEUTICALS, INC.
58 SOUTH SERVICE ROAD
SUITE 110
MELVILLE, NEW YORK 11747.

SERIAL NUMBER: 09047966

FILING DATE: 03/25/1998

PATENT NUMBER:

ISSUE DATE:

TITLE: METHODS OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION

SERIAL NUMBER: 09711272 FILING DATE: 11/09/2000
PATENT NUMBER: ISSUE DATE:
TITLE: STABLE POLYMORPH ON N-(3-ETHYNYLPHENYL)-6, 7-BIS (2METHOXYETHOXY)-4-
QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND
PHARMACEUTICAL USES THEREOF

SERIAL NUMBER: 09709103 FILING DATE: 11/08/2000
PATENT NUMBER: 6733991 ISSUE DATE: 05/11/2004
TITLE: AGS PROTEINS AND NUCLEIC ACID MOLECULES AND USES THEREFOR

SERIAL NUMBER: 09454074 FILING DATE: 12/02/1999
PATENT NUMBER: ISSUE DATE:
TITLE: COMPOUNDS SPECIFIC TO ADENOSINE A1 RECEPTOR AND USES THEREOF

SERIAL NUMBER: 09439410 FILING DATE: 11/11/1999
PATENT NUMBER: 6746852 ISSUE DATE: 06/08/2004
TITLE: AGS PROTEINS AND NUCLEIC ACID MOLECULES AND USES THEREOF

SERIAL NUMBER: 09728616 FILING DATE: 12/01/2000
PATENT NUMBER: ISSUE DATE:
TITLE: COMPOUNDS SPECIFIC TO ADENOSINE A3 RECEPTOR AND USES THEREOF

SERIAL NUMBER: 09728229 FILING DATE: 12/01/2000
PATENT NUMBER: 6800633 ISSUE DATE: 10/05/2004
TITLE: PYRROLO [2, 3D] PYRIMIDINE COMPOSITIONS AND THEIR USE

SERIAL NUMBER: 10716098 FILING DATE: 11/17/2003
PATENT NUMBER: ISSUE DATE:
TITLE: N- (3-ETHYNYLPHENYL) -6, 7-BIS (2-METHOXYETHOXY) -4-QUINAZOLINAMINE
MESYLATED ANHYDRATE AND MONOHYDRATE

SERIAL NUMBER: 08370227 FILING DATE: 01/09/1995
PATENT NUMBER: 5817625 ISSUE DATE: 10/06/1998
TITLE: METHODS OF PREVENTION OF ORAL MUCOSITIS WITH TRANSFORMING GROWTH
FACTOR BETA

SERIAL NUMBER: 08778754 FILING DATE: 01/06/1997
PATENT NUMBER: 6136779 ISSUE DATE: 10/24/2000
TITLE: METHODS OF SPECIFICALLY TRANSCRIPTIONALLY MODULATING THE EXPRESSION
OF A GENE OF INTEREST

SERIAL NUMBER: 09454075 FILING DATE: 12/02/1999
PATENT NUMBER: 6686366 ISSUE DATE: 02/03/2004
TITLE: COMPOUNDS SPECIFIC TO ADENOSINE A3 RECEPTOR AND USES THEREOF

SERIAL NUMBER: 09363877 FILING DATE: 07/29/1999
PATENT NUMBER: 6465495 ISSUE DATE: 10/15/2002
TITLE: PREPARATION OF PYRIDONE-BASED PHOSPHOTYROSINE MIMETICS AND USES
THEREOF

SERIAL NUMBER: 09728607 FILING DATE: 12/01/2000
PATENT NUMBER: 6664252 ISSUE DATE: 12/16/2003
TITLE: 4-AMINOPYRROLO [2,3-D] PYRIMIDINE COMPOUNDS SPECIFIC TO ADENOSINE
A2A RECEPTOR AND USES THEREOF

SERIAL NUMBER: 09728316 FILING DATE: 12/01/2000
PATENT NUMBER: 6680322 ISSUE DATE: 01/20/2004
TITLE: COMPOUNDS SPECIFIC TO ADENOSINE A1 RECEPTORS AND USES THEREOF

SERIAL NUMBER: 08457097 FILING DATE: 06/01/1995
PATENT NUMBER: 6425769 ISSUE DATE: 07/30/2002
TITLE: TISSUE-DERIVED TUMOR GROWTH INHIBITORS, METHODS OF PREPARATION AND USES THEREOF

SERIAL NUMBER: 07543341 FILING DATE: 06/25/1990
PATENT NUMBER: 5262319 ISSUE DATE: 11/16/1993
TITLE: A METHOD FOR OBTAINING BONE MARROW FREE OF TUMOR CELLS USING TRANSFORMING GROWTH FACTOR-B3

SERIAL NUMBER: 08115519 FILING DATE: 09/01/1993
PATENT NUMBER: 5824297 ISSUE DATE: 10/20/1998
TITLE: TISSUE-DERIVED TUMOR GROWTH INHIBITORS, METHODS OF PREPARATION AND USES THEREOF

SERIAL NUMBER: 08476014 FILING DATE: 06/07/1995
PATENT NUMBER: 5871724 ISSUE DATE: 02/16/1999
TITLE: TISSUE-DERIVED TUMOR GROWTH INHIBITORS, METHODS OF PREPARATION AND USES THEREOF

SERIAL NUMBER: 08188197 FILING DATE: 01/27/1994
PATENT NUMBER: 6586394 ISSUE DATE: 07/01/2003
TITLE: TISSUE-DERIVED TUMOR GROWTH INHIBITORS

SERIAL NUMBER: 08294061 FILING DATE: 08/22/1994
PATENT NUMBER: 6559123 ISSUE DATE: 05/06/2003
TITLE: TISSUE-DERIVED TUMOR GROWTH INHIBITORS, METHODS OF PREPARATION AND USES THEREOF

SERIAL NUMBER: 07304947 FILING DATE: 02/01/1989
PATENT NUMBER: 5190858 ISSUE DATE: 03/02/1993
TITLE: MONOCLONAL ANTIBODIES DIRECTED TO EPITOPEs OF HUMAN TRANSFORMING GROWTH FACTOR - ALPHA AND USES THEREOF

SERIAL NUMBER: 08267834 FILING DATE: 06/28/1994
PATENT NUMBER: 5665543 ISSUE DATE: 09/09/1997
TITLE: METHOD OF DISCOVERING CHEMICALS CAPABLE OF FUNCTIONING AS GENE EXPRESSION MODULATORS

SERIAL NUMBER: 09123728 FILING DATE: 07/28/1998
PATENT NUMBER: 6376175 ISSUE DATE: 04/23/2002
TITLE: METHODS OF DISCOVERING CHEMICALS CAPABLE OF FUNCTIONING AS GENE EXPRESSION MODULATORS

SERIAL NUMBER: 08683455 FILING DATE: 07/18/1996
PATENT NUMBER: 5976793 ISSUE DATE: 11/02/1999
TITLE: METHODS OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION AND OF DISCOVERING CHEMICALS CAPABLE OF FUNCTIONING AS GENE EXPRESSION MODULATORS

SERIAL NUMBER: 08779230 FILING DATE: 01/06/1997
PATENT NUMBER: 5863733 ISSUE DATE: 01/26/1999
TITLE: METHODS OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION AND OF
DISCOVERING CHEMICALS CAPABLE OF FUNCTIONING AS GENE EXPRESSION
MODULATORS

SERIAL NUMBER: 08255236 FILING DATE: 06/07/1994
PATENT NUMBER: 6203976 ISSUE DATE: 03/20/2001
TITLE: METHODS OF PREPARING COMPOSITIONS COMPRISING CHEMICALS CAPABLE OF
TRANSCRIPTIONAL MODULATION

SERIAL NUMBER: 08463691 FILING DATE: 06/05/1995
PATENT NUMBER: 6165712 ISSUE DATE: 12/26/2000
TITLE: METHODS OF TRANSCRIPTIONALLY MODULATING EXPRESSION OF VIRAL GENES
AND GENES USEFUL FOR PRODUCTION OF PROTEINS

SERIAL NUMBER: 07832905 FILING DATE: 02/07/1992
PATENT NUMBER: 5580722 ISSUE DATE: 12/03/1996
TITLE: METHODS OF DETERMINING CHEMICALS THAT MODULATE EXPRESSION OF GENES
ASSOCIATED WITH CARDIOVASCULAR DISEASE

SERIAL NUMBER: 08700757 FILING DATE: 08/15/1996
PATENT NUMBER: 5846720 ISSUE DATE: 12/08/1998
TITLE: METHODS OF DETERMINING CHEMICALS THAT MODULATE EXPRESSION OF GENES
ASSOCIATED WITH CARDIOVASCULAR DISEASE

SERIAL NUMBER: 08463398 FILING DATE: 06/05/1995
PATENT NUMBER: 6589733 ISSUE DATE: 07/08/2003
TITLE: METHODS OF PREPARING COMPOSITIONS COMPRISING CHEMICALS CAPABLE OF
TRANSCRIPTIONAL MODULATION

SERIAL NUMBER: 08458691 FILING DATE: 06/02/1995
PATENT NUMBER: 5776502 ISSUE DATE: 07/07/1998
TITLE: METHODS OF TRANSCRIPTIONALLY MODULATING GENE EXPRESSION

SERIAL NUMBER: 07292263 FILING DATE: 12/30/1988
PATENT NUMBER: 5217896 ISSUE DATE: 06/08/1993
TITLE: MONOCLONAL ANTIBODIES RECOGNIZING PARATHYROID HORMONE - LIKE PROTEIN

SERIAL NUMBER: 08395909 FILING DATE: 02/28/1995
PATENT NUMBER: 5635489 ISSUE DATE: 06/03/1997
TITLE: METHODS OF PREVENTION OF ORAL MUCOSITIS WITH TRANSFORMING GROWTH
FACTOR BETA

SERIAL NUMBER: 09069693 FILING DATE: 04/29/1998
PATENT NUMBER: 5985913 ISSUE DATE: 11/16/1999
TITLE: YETRACYCLIC COMPOUNDS FOR ENHANCING BIOSYNTHESIS OF ERYTHROPOIETIN,
COMPOSITIONS CONTAINING SAME, AND METHODS OF USE THEREOF

SERIAL NUMBER: 09086168 FILING DATE: 05/28/1998
PATENT NUMBER: 6638941 ISSUE DATE: 10/28/2003
TITLE: CONFORMATIONALLY CONSTRAINED PEPTIDOMIMETICS AS BETA-TURN TEMPLATES
AND MODULATORS OF SH3 DOMAINS

SERIAL NUMBER: 08864240	FILING DATE: 05/28/1997
PATENT NUMBER: 6037340	ISSUE DATE: 03/14/2000
TITLE: SYNTHESIS AND USE OF THIOPHENE- AND PYRROLE-BASED HETEROAROMATIC COMPOUNDS	
SERIAL NUMBER: 09198697	FILING DATE: 11/24/1998
PATENT NUMBER: 6376667	ISSUE DATE: 04/23/2002
TITLE: SOLID PHASE SYNTHESIS OF HETEROCYCLES	
SERIAL NUMBER: 09355534	FILING DATE: 07/29/1999
PATENT NUMBER: 6706721	ISSUE DATE: 03/16/2004
TITLE: N- (3-ETHYNYLPHENYLAMINO) -6,7-BIS(2-METHOXYETHOXY) -4-QUINAZOLINAMINE MESYLA TE ANHYDRATE AND MONOHYDRATE	

SHARON LATIMER, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

04-07-2004

Docket No. 1919/21601/JPW/G

FORM PTO-1595 (Substitute)
(Rev. 8-96)

To the Honorable Commissioner of

1. Name of conveying party(ies):

OSI Pharmaceuticals, Inc.

102715280

4.6-64

Additional name(s) of conveying party(ies) attached?

 Yes No

3. Nature of Conveyance:

<input type="checkbox"/> Assignment	<input type="checkbox"/> Merger
<input type="checkbox"/> Security Agreement	<input type="checkbox"/> Change of Name
<input checked="" type="checkbox"/> Other <u>Change of address</u>	

Execution Date(s): April 10, 2002

4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date(s) of the application is(are):

A. Patent Application No.(s) see attached sheets
(2 pages)B. Patent No.(s) see attached sheets (2 pages)

Additional numbers attached?

 Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: John P. White

Internal Address: Cooper & Dunham LLP

Street Address: 1185 Avenue of the Americas

City/State/Zip: New York, New York 10036

6. Total number of applications and patents involved: 59

7. Total fee (37 CFR §3.41): \$ 2,360.00

 Enclosed Authorized to be charged to deposit account

8. Deposit account number:

03-3125

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Gary J. Gershik

Name of Person Signing

Reg. No. 39,992

Signature

April 2, 2004

Date

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

John P. White
Reg. No. 128,678
Gary J. Gershik
Reg. No. 39,992

Date

Total Number of pages including cover sheet, attachments and document: 4

OFFICE OF PRACTICE
FINANCIAL SECTION
MAY 6 2004
400

OMB No. 0651-0011 (exp. 4/94)

Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Continuation of Box No. 4:

<u>Patent Application No. (s)</u>	<u>Filing Dates</u>
09/047,966	March 25, 1998
09/711,272	November 19, 2000
09/709,103	November 8, 2000
09/454,074	December 2, 1999
09/439,410	November 11, 1999
09/728,616	December 1, 2000
09/728,229	December 1, 2000
10/716,098	November 17, 2003
<u>Patent No. (s)</u>	<u>Issue Dates</u>
5,262,319	November 16, 1993
5,580,722	December 3, 1996
5,824,297	October 20, 1998
6,203,976	March 20, 2001
5,817,625	October 6, 1998
6,425,769	July 30, 2002
6,165,712	December 26, 2000
5,846,720	December 8, 1998
6,586,394	July 1, 2003
5,665,543	September 9, 1997
5,635,489	June 3, 1997
5,776,502	July 7, 1998
5,871,724	February 16, 1996
6,136,779	October 24, 2000
6,376,175	April 23, 2002
6,559,123	May 6, 2003
6,589,733	July 8, 2003
5,976,793	November 2, 1999
5,863,733	January 26, 1999
5,985,913	November 16, 1999
6,686,366	February 3, 2004
6,465,495	October 15, 2002
6,664,252	December 16, 2003
6,680,322	January 20, 2004
6,037,340	March 15, 2000
6,706,721	March 16, 2004
6,425,769	July 30, 2002
5,262,319	November 16, 1993
5,824,297	October 20, 1998
5,871,724	February 16, 1999
6,586,394	July 1, 2003
6,559,123	May 6, 2003
5,190,858	March 2, 1993

Continuation of Box No. 4:

Patent No. (s) Issue Dates

5,665,543	September 9, 1997
6,376,175	April 23, 2002
5,976,793	November 2, 1999
5,863,733	January 26, 1999
6,136,779	October 24, 2000
6,203,976	March 20, 2001
6,165,712	December 26, 2000
5,580,722	December 3, 1996
5,846,720	December 8, 1998
6,589,733	July 8, 1998
5,776,502	July 7, 1998
5,217,896	June 8, 1993
5,635,489	June 3, 1997
5,985,913	November 16, 1999
6,638,941	October 28, 2003
6,037,340	March 14, 2000
6,376,667	April 23, 2002
6,706,721	March 16, 2004

**CERTIFICATE OF AMENDMENT OF
APPLICATION FOR AUTHORITY
OF
OSI PHARMACEUTICALS, INC.
UNDER SECTION 1309-A OF THE BUSINESS CORPORATION LAW**

Pursuant to the provisions of the New York Business Corporation Law, the undersigned corporation hereby makes the following statements:

1. The name of the corporation as it appears on the index of names in the Department of State is: OSI Pharmaceuticals, Inc.
2. It is incorporated under the laws of Delaware.
3. The date it was authorized to do business in New York was April 29, 1983.
4. The Application for Authority is amended to change the address of the principal office of the corporation to:

58 South Service Road, Suite 110
Melville, New York 11747

In:

Suffolk County

IN WITNESS WHEREOF, OSI Pharmaceuticals, Inc., the corporation hereinbefore mentioned and described, has caused this certificate to be signed in its name by Robert L. Van Nostrand, its Vice President and Chief Financial Officer, this 10th day of April, 2002, and the statements contained therein are affirmed as true under penalties of perjury.

OSI PHARMACEUTICALS, INC.

